KR20130094710A - Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 - Google Patents

Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 Download PDF

Info

Publication number
KR20130094710A
KR20130094710A KR1020127029826A KR20127029826A KR20130094710A KR 20130094710 A KR20130094710 A KR 20130094710A KR 1020127029826 A KR1020127029826 A KR 1020127029826A KR 20127029826 A KR20127029826 A KR 20127029826A KR 20130094710 A KR20130094710 A KR 20130094710A
Authority
KR
South Korea
Prior art keywords
alkyl
ring
formula
compound
hetar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127029826A
Other languages
English (en)
Korean (ko)
Inventor
마크 로렌스 보이즈
로렌스 이. 버지스
로버트 디. 그로네버그
대런 엠. 하비
릴리 후앙
티모시 커쳐
크리스토퍼 에프. 크레이져
엘렌 레어드
유진 탈턴
첸 자오
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20130094710A publication Critical patent/KR20130094710A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020127029826A 2010-04-14 2011-04-11 Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 Withdrawn KR20130094710A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32418610P 2010-04-14 2010-04-14
US61/324,186 2010-04-14
PCT/US2011/031896 WO2011130146A1 (en) 2010-04-14 2011-04-11 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Publications (1)

Publication Number Publication Date
KR20130094710A true KR20130094710A (ko) 2013-08-26

Family

ID=43984073

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127029826A Withdrawn KR20130094710A (ko) 2010-04-14 2011-04-11 Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘

Country Status (21)

Country Link
US (1) US8962596B2 (https=)
EP (1) EP2558468B1 (https=)
JP (2) JP2013523884A (https=)
KR (1) KR20130094710A (https=)
CN (1) CN102985424B (https=)
AR (1) AR081075A1 (https=)
AU (1) AU2011240808B2 (https=)
CA (1) CA2796388A1 (https=)
CL (1) CL2012002882A1 (https=)
CO (1) CO6630187A2 (https=)
CR (1) CR20120572A (https=)
MX (1) MX2012011941A (https=)
NZ (1) NZ603446A (https=)
PH (1) PH12012502046A1 (https=)
RU (1) RU2012148246A (https=)
SG (1) SG184870A1 (https=)
TW (1) TWI494314B (https=)
UA (1) UA109131C2 (https=)
UY (1) UY33328A (https=)
WO (1) WO2011130146A1 (https=)
ZA (1) ZA201208544B (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US20140228349A1 (en) * 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
CA2854879A1 (en) * 2011-11-07 2013-05-16 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2912031B1 (en) 2012-10-24 2017-05-31 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
EP2951590A1 (en) 2013-02-04 2015-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
WO2014146249A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
EA201591881A1 (ru) * 2013-03-28 2016-04-29 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
SMT201900223T1 (it) * 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
RS59144B1 (sr) 2013-11-13 2019-09-30 Vertex Pharma Inhibitori replikacije virusa influence
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
ES2791252T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
HUE054371T2 (hu) 2014-12-05 2021-09-28 Array Biopharma Inc 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
EP3248980B1 (en) 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
ES2734048T3 (es) * 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
ES2822748T3 (es) 2015-05-29 2021-05-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de cinasa Janus
AR104918A1 (es) * 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
JP6770580B2 (ja) * 2016-01-26 2020-10-14 杭州華東医薬集団生物医薬有限公司Ｈａｎｇｚｈｏｕ Ｈｕａｄｏｎｇ Ｍｅｄｉｃｉｎｅ Ｇｒｏｕｐ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピロロピリミジン５員環アザ環状誘導体およびその利用
CR20180372A (es) 2016-02-24 2018-09-19 Pfizer Derivados de pirazolo [1,5-a] pirazin-4-ilo
JP7112755B2 (ja) 2017-01-23 2022-08-04 シャンハイ ロングウッド バイオファーマシューティカルズ カンパニー リミテッド Ｊａｋ酵素阻害剤及びその製造方法と用途
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
EP3666770A4 (en) 2017-08-07 2021-04-07 Joint Stock Company "Biocad" NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
WO2019034973A1 (en) * 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
IL311485B1 (en) 2018-02-16 2026-01-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
TW202028209A (zh) * 2018-09-27 2020-08-01 大陸商重慶複創醫藥研究有限公司 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
CN113924301B (zh) * 2019-04-12 2024-08-16 北京普祺医药科技股份有限公司 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
FI4157831T3 (fi) 2020-06-02 2024-12-02 Incyte Corp Menetelmiä jak1-estäjän valmistamiseksi
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022125670A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
RS67455B1 (sr) 2021-05-03 2025-12-31 Incyte Corp Inhibitori jak1 puta za lečenje prurigo nodularisa
AU2022387652B2 (en) * 2021-11-12 2025-10-16 Cms Research & Development Pte. Ltd. Pyrazolo fused ring compound and use thereof
KR20250005346A (ko) * 2022-04-25 2025-01-09 일라이 릴리 앤드 캄파니 Fgfr2 저해제 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6313129B1 (en) 1998-08-21 2001-11-06 Hughes Institute Therapeutic compounds
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
EP2455382B1 (en) * 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds

Also Published As

Publication number Publication date
UA109131C2 (ru) 2015-07-27
EP2558468A1 (en) 2013-02-20
CN102985424A (zh) 2013-03-20
TW201134827A (en) 2011-10-16
CA2796388A1 (en) 2011-10-20
JP2013523884A (ja) 2013-06-17
US20130131039A1 (en) 2013-05-23
TWI494314B (zh) 2015-08-01
UY33328A (es) 2012-10-31
PH12012502046A1 (en) 2017-07-26
EP2558468B1 (en) 2015-04-01
ZA201208544B (en) 2015-04-29
SG184870A1 (en) 2012-11-29
CL2012002882A1 (es) 2013-02-08
AR081075A1 (es) 2012-06-06
US8962596B2 (en) 2015-02-24
AU2011240808A1 (en) 2012-11-29
CN102985424B (zh) 2015-03-11
CR20120572A (es) 2013-02-20
NZ603446A (en) 2014-05-30
RU2012148246A (ru) 2014-05-20
WO2011130146A1 (en) 2011-10-20
JP2015205905A (ja) 2015-11-19
CO6630187A2 (es) 2013-03-01
MX2012011941A (es) 2013-08-27
AU2011240808B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
CN111511738B (zh) 杂芳类衍生物调节剂、其制备方法和应用
AU2018201557B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
EP2430013B1 (en) Heteroaryl compounds as pikk inhibitors
TW201326173A (zh) ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶
JP2011529920A (ja) ピリミジン化合物、組成物及び使用方法
MX2012010050A (es) Inhibidores de pirrolopirazina cinasa.
AU2010249380A1 (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
JP2024167319A (ja) ＮＦ－κＢ誘導キナーゼの低分子阻害剤
AU2015201991A1 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
US20250282785A1 (en) Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase
EP4313300A1 (en) Pharmaceutical compound

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid